Comparison of prognoses according to non-positive and positive spectrin ???± II expression detected immunohistochemically in epithelial ovarian carcinoma: a retrospective study.

摘要

Abstract Anticancer drug sensitivity affects prognosis in ovarian carcinoma. Previously, we purified spectrin ???± II and ???2 II tetramers from cisplatin-resistant ovarian serous adenocarcinoma cells and demonstrated that they contribute to platinum anticancer drug resistance. In this clinical study, we focused on the role of spectrin ???± II expression. It is our objective to demonstrate the potential of spectrin ???± II expression as a useful predictor of anticancer drug resistance and postoperative prognosis in epithelial ovarian carcinoma. Spectrin ???± II expression in the ovarian adenocarcinoma surgical specimens of 193 patients was examined by immunohistochemical staining. Staining strength was scored 3+, regarded as positive expression, and 2+, 1+, and 0, regarded as non-positive expression. Prognoses obtained from clinical records were evaluated by statistical analysis. In the 193 cases studied, positive spectrin ???± II expression was associated with worse overall survival when compared with non-positive expression ( P < 0.001 by log-rank test), and spectrin ???± II expression was identified as an independent predictive factor of overall survival (hazard ratio[HR]: 3.77, 95% confidence interval[CI]: 1.77?￠????8.00; P < 0.001 by multivariate Cox's proportional hazards model). In the study about progression-free survival, spectrin ???± II expression was not associated with prognoses. However, similar results as overall survival were obtained for survival after recurrence of the 92 recurrent cases ( P = 0.0051 by log-rank test, HR: 4.49, 95% CI: 2.06?￠????9.79; P < 0.001 by multivariate Cox's proportional hazards model). In a detailed overall survival study of 66 serous adenocarcinoma patients and 127 nonserous adenocarcinoma patients, similar results were also obtained. Spectrin ???± II expression is a useful predictor of anticancer drug resistance and postoperative prognosis in epithelial ovarian carcinoma..